Publicacións nas que colabora con Pablo García Pavía (44)

2024

  1. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

    The New England journal of medicine, Vol. 390, Núm. 20, pp. 1849-1861

  2. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

    Journal of the American Heart Association, Vol. 13, Núm. 15, pp. e035993

  3. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

    Journal of Cardiac Failure

  4. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM

    Journal of the American College of Cardiology, Vol. 84, Núm. 19, pp. 1821-1831

  5. Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives

    Journal of the American College of Cardiology, Vol. 83, Núm. 17, pp. 1640-1651

  6. Phenotype and Clinical Outcomes in Desmin-Related Arrhythmogenic Cardiomyopathy

    JACC: Clinical Electrophysiology, Vol. 10, Núm. 6, pp. 1178-1190

  7. Pregnancy in women with dilated cardiomyopathy genetic variants

    Revista Espanola de Cardiologia

  8. Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy

    ESC Heart Failure

  9. REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNARelated Dilated Cardiomyopathy

    Circulation: Heart Failure, Vol. 17, Núm. 7, pp. e011548

  10. Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM

    Journal of the American College of Cardiology, Vol. 84, Núm. 19, pp. 1839-1849

2023

  1. 2023 ESC Guidelines for the management of cardiomyopathies

    European heart journal, Vol. 44, Núm. 37, pp. 3503-3626

  2. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 42-53

  3. Emery-Dreifuss muscular dystrophy Type 1 is associated with a high risk of malignant ventricular arrhythmias and end-stage heart failure

    European Heart Journal, Vol. 44, Núm. 48, pp. 5064-5073

  4. Linee guida ESC 2023 per il trattamento delle cardiomiopatie elaborate dalla task force per il trattamento delle cardiomiopatie della Società Europea di Cardiologia (ESC)

    Giornale italiano di cardiologia (2006), Vol. 24, Núm. 11, pp. 1e-127e

  5. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

    Journal of the American College of Cardiology, Vol. 81, Núm. 1, pp. 34-45

  6. Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in Spain

    Amyloid, Vol. 30, Núm. 2, pp. 199-207

  7. Risks of Ventricular Arrhythmia and Heart Failure in Carriers of RBM20 Variants

    Circulation: Genomic and Precision Medicine, Vol. 16, Núm. 5, pp. 434-441

2022

  1. Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy

    European Journal of Heart Failure, Vol. 24, Núm. 7, pp. 1183-1196

  2. Erratum: Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator (European Heart Journal (2022) (ehac235) DOI: 10.1093/eurheartj/ehac235)

    European Heart Journal

  3. Genotype-phenotype correlations in hypertrophic cardiomyopathy: a multicenter study in Portugal and Spain of the TPM1 p.Arg21Leu variant

    Revista Espanola de Cardiologia, Vol. 75, Núm. 3, pp. 242-250